@article{ac40c341872742feb0f92c81d264a9ce,
title = "A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma",
abstract = "So far, two genes associated with familial melanoma have been identified, accounting for a minority of genetic risk in families. Mutations in CDKN2A account for approximately 40% of familial cases, and predisposing mutations in CDK4 have been reported in a very small number of melanoma kindreds. Here we report the whole-genome sequencing of probands from several melanoma families, which we performed in order to identify other genes associated with familial melanoma. We identify one individual carrying a novel germline variant (coding DNA sequence c.G1075A; protein sequence p.E318K; rs149617956) in the melanoma-lineage-specific oncogene microphthalmia-associated transcription factor (MITF). Although the variant co-segregated with melanoma in some but not all cases in the family, linkage analysis of 31 families subsequently identified to carry the variant generated a log of odds (lod) score of 2.7 under a dominant model, indicating E318K as a possible intermediate risk variant. Consistent with this, the E318K variant was significantly associated with melanoma in a large Australian case-control sample. Likewise, it was similarly associated in an independent case-control sample from the United Kingdom. In the Australian sample, the variant allele was significantly over-represented in cases with a family history of melanoma, multiple primary melanomas, or both. The variant allele was also associated with increased naevus count and non-blue eye colour. Functional analysis of E318K showed that MITF encoded by the variant allele had impaired sumoylation and differentially regulated several MITF targets. These data indicate that MITF is a melanoma-predisposition gene and highlight the utility of whole-genome sequencing to identify novel rare variants associated with disease susceptibility.",
author = "Satoru Yokoyama and Woods, {Susan L.} and Boyle, {Glen M.} and Aoude, {Lauren G.} and Stuart MacGregor and Victoria Zismann and Michael Gartside and Cust, {Anne E.} and Rizwan Haq and Mark Harland and Taylor, {John C.} and Duffy, {David L.} and Kelly Holohan and Ken Dutton-Regester and Palmer, {Jane M.} and Vanessa Bonazzi and Stark, {Mitchell S.} and Judith Symmons and Law, {Matthew H.} and Christopher Schmidt and Cathy Lanagan and Linda O'Connor and Holland, {Elizabeth A.} and Helen Schmid and Maskiell, {Judith A.} and Jodie Jetann and Megan Ferguson and Jenkins, {Mark A.} and Kefford, {Richard F.} and Giles, {Graham G.} and Armstrong, {Bruce K.} and Aitken, {Joanne F.} and Hopper, {John L.} and Whiteman, {David C.} and Pharoah, {Paul D.} and Easton, {Douglas F.} and Dunning, {Alison M.} and Newton-Bishop, {Julia A.} and Montgomery, {Grant W.} and Martin, {Nicholas G.} and Mann, {Graham J.} and Bishop, {D. Timothy} and Hensin Tsao and Trent, {Jeffrey M.} and Fisher, {David E.} and Hayward, {Nicholas K.} and Brown, {Kevin M.}",
note = "Funding Information: Acknowledgements This work was supported by team science awards by the Melanoma Research Alliance (J.M.T., N.K.H., H.T. and D.E.F.), the American Cancer Society (K.M.B., RSG-08-200-01), the National Institutes of Health (NIH; D.E.F., AR043369-14; N.K.H., CA88363; H.T., K24CA149202 and P50CA93683), Doris Duke Medical Foundation (D.E.F.), Dr Miriam and Sheldon G. Adelson Medical Research Foundation (D.E.F.), US-Israel Binational Science Foundation (D.E.F.), and the Division of Cancer Epidemiology and Genetics of the National Cancer Institute (K.M.B.). N.K.H., D.L.D., S.M. and G.W.M. are supported by National Health and Medical Research Council of Australia (NHMRC) research fellowships. M.H.L. is supported by Cancer Australia grant 1011143. The collection of samples in the Leeds-based case–control study (the Melanoma Cohort Study) was funded by Cancer Research UK (Project Grant C8216/A6129 and Programme awards C588/A4994 and C588/A10589) and by the NIH (R01 CA83115). Recruitment was facilitated by the UK National Cancer Research Network. We thank S. Leake, S. Haynes, S. Waseem for Leeds case–control data collection; and H. Snowdon and C. Taylor from the Leeds Cancer Research UK Cancer Centre Genomics Facility for the genotyping of the UK samples. AMFS was supported by the NHMRC (project grants 566946, 107359, 211172 and program grant number 402761 to G.J.M. and R.F.K.); the Cancer Council New South Wales (project grant 77/ 00, 06/10), the Cancer Council Victoria and the Cancer Council Queensland (project grant371); and the NIH (via RO1grantCA-83115-01A2 to the international Melanoma Genetics Consortium—GenoMEL). The University of Cambridge SEARCH study was supported by Cancer Research UK Programme awards (C490/A11021 and C8197/ A10123). A.E.C. is the recipient of an NHMRC public health postdoctoral fellowship (520018) and a Cancer Institute NSW Early Career Development Fellowship (10/ECF/ 2-06).B.K.A. issupported bya UniversityofSydneyMedicalFoundationProgram Grant and J.L.H. is an Australia Fellow of the NHMRC. We gratefully acknowledge all of the participants, the work and dedication of the research coordinators, interviewers, examiners and data management staff, including J. Arbuckle, S. Columbus, M. Lang,",
year = "2011",
month = dec,
day = "1",
doi = "10.1038/nature10630",
language = "英語",
volume = "480",
pages = "99--103",
journal = "Nature",
issn = "0028-0836",
publisher = "Nature Research",
number = "7375",
}